These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26993770)

  • 21. Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol.
    Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
    Adv Clin Exp Med; 2018 Jul; 27(7):941-945. PubMed ID: 30019863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis.
    Zheng SR; Guo GL; Zhang W; Huang GL; Hu XQ; Zhu J; Huang QD; You J; Zhang XH
    Oncol Rep; 2012 Apr; 27(4):1149-55. PubMed ID: 22245916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo.
    Peng X; Cao P; Li J; He D; Han S; Zhou J; Tan G; Li W; Yu F; Yu J; Li Z; Cao K
    Cancer Biol Ther; 2015; 16(2):261-7. PubMed ID: 25756509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.
    Ren Y; Zhou X; Yang JJ; Liu X; Zhao XH; Wang QX; Han L; Song X; Zhu ZY; Tian WP; Zhang L; Mei M; Kang CS
    Cancer Lett; 2015 Jul; 362(2):174-82. PubMed ID: 25827073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.
    Wang B; Li J; Sun M; Sun L; Zhang X
    IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of LncRNA-GACAT3 with MRI features of breast cancer and its molecular mechanism.
    Hu H; Wang Y; Zhang T; Zhang C; Liu Y; Li G; Zhou D; Lu S
    J BUON; 2019; 24(6):2377-2384. PubMed ID: 31983109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downregulation of GSK3B by miR-132-3p Enhances Etoposide-Induced Breast Cancer Cell Apoptosis.
    Xu C; Du Z; Ren S; Pian Y
    Ann Clin Lab Sci; 2021 May; 51(3):285-294. PubMed ID: 34162557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1.
    Zheng M; Sun X; Li Y; Zuo W
    Tumour Biol; 2016 Jun; 37(6):8189-96. PubMed ID: 26715279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-193a and taxol combination: A new strategy for treatment of colorectal cancer.
    Hejazi M; Baghbani E; Amini M; Rezaei T; Aghanejad A; Mosafer J; Mokhtarzadeh A; Baradaran B
    J Cell Biochem; 2020 Feb; 121(2):1388-1399. PubMed ID: 31512793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sperm-associated antigen 9 overexpression correlates with poor prognosis and insensitive to Taxol treatment in breast cancer.
    Yang C; Shen B; Zhang J; Zhang Q
    Biomarkers; 2016; 21(1):62-7. PubMed ID: 26631164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.
    Petrović N; Mandušić V; Stanojević B; Lukić S; Todorović L; Roganović J; Dimitrijević B
    Med Oncol; 2014 Mar; 31(3):867. PubMed ID: 24488617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer.
    Chen J; Chen Y; Chen Z
    Cancer Invest; 2013 Jan; 31(1):17-23. PubMed ID: 23327190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
    Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
    Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.
    Xue J; Chi Y; Chen Y; Huang S; Ye X; Niu J; Wang W; Pfeffer LM; Shao ZM; Wu ZH; Wu J
    Oncogene; 2016 Jan; 35(4):448-58. PubMed ID: 25867061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.